Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02207920 · ClinicalTrials.gov registry record · Phase 1
Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 104
- Enrollment target
NCT02207920 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 104 participants.
The verdict
NCT02207920, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 104 participants
- Enrollment target
Study Summary
This study will evaluate the safety, tolerability, and immune response to different combinations of two experimental HIV vaccines-the DNA-HIV-PT123 vaccine and the AIDSVAX® B/E vaccine-in healthy adults who are not infected with HIV.
Interventions
- BIOLOGICAL AIDSVAX B/E Vaccine
- BIOLOGICAL DNA-HIV-PT123 Vaccine
- BIOLOGICAL Placebo for DNA-HIV-PT123
- BIOLOGICAL Placebo for AIDSVAX B/E
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2014-07 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02207920
The ClinicalTrials.gov registry entry for NCT02207920 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which AIDSVAX B/E Vaccine is the first listed.
NCT02207920 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02207920 about?
NCT02207920 is a clinical study titled "Evaluating the Safety and Immune Response to Different Combinations of the DNA-HIV-PT123 and AIDSVAX® B/E Vaccines in Healthy, HIV-Uninfected Adults". This study will evaluate the safety, tolerability, and immune response to different combinations of two experimental HIV vaccines-the DNA-HIV-PT123 vaccine and the AIDSVAX® B/E vaccine-in healthy adults who are not infected with HIV.
What is the current status of trial NCT02207920?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 104 participants. The study started on 2014-07. Estimated completion is 2015-12.
What interventions are being tested in trial NCT02207920?
The interventions under investigation include: AIDSVAX B/E Vaccine (BIOLOGICAL), DNA-HIV-PT123 Vaccine (BIOLOGICAL), Placebo for DNA-HIV-PT123 (BIOLOGICAL), Placebo for AIDSVAX B/E (BIOLOGICAL).
Who is sponsoring clinical trial NCT02207920?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.